Roger Williams Medical Center, Providence, RI 02908.
Roger Williams Medical Center, Providence, RI 02908.
Hum Pathol. 2018 Aug;78:54-62. doi: 10.1016/j.humpath.2018.04.007. Epub 2018 Apr 22.
More than 500 women worldwide have developed a CD30+ T-cell lymphoma around breast implants, strongly suggesting a cause-and-effect relationship, and designated as breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). The mechanism of lymphomagenesis is unknown. Recently, a bacterial biofilm containing gram-negative bacilli was discovered on the surface of breast implants associated with ALCL. We and others have described overexpression of the proto-oncogene JUNB and mutations of JAK1/2, TP53 and STAT3 in BIA-ALCL. Here we report that BIA-ALCL cell lines and anaplastic lymphoma cells in clinical specimens produce IL-13, the signature cytokine of allergic inflammation. Supporting the link of BIA-ALCL to allergic inflammation, lymphoma cells were often surrounded by eosinophils and mast cells, features typically absent in systemic ALCL. Because of the link of IL-13 to allergy, we looked for IgE and found it decorating the surface of mast cells and antigen-presenting follicular dendritic cells in capsules and lymph nodes infiltrated by anaplastic lymphoma cells, but not uninvolved capsules. Plasma cells within capsules and regional lymph nodes were identified as a possible source of IgE. Together, these findings suggest the hypothesis that an amplified immune response with features of a chronic allergic reaction in a susceptible patient underlies the pathogenesis of BIA-ALCL.
全球有 500 多名女性在乳房植入物周围患上 CD30+ T 细胞淋巴瘤,强烈提示存在因果关系,并被指定为乳房植入物相关间变性大细胞淋巴瘤(BIA-ALCL)。淋巴瘤发生的机制尚不清楚。最近,在与 ALCL 相关的乳房植入物表面发现了一种含有革兰氏阴性菌的细菌生物膜。我们和其他人已经描述了在 BIA-ALCL 中原癌基因 JUNB 的过度表达以及 JAK1/2、TP53 和 STAT3 的突变。在这里,我们报告 BIA-ALCL 细胞系和临床标本中的间变性大细胞淋巴瘤细胞产生白细胞介素-13,这是过敏炎症的特征性细胞因子。支持 BIA-ALCL 与过敏炎症的联系,淋巴瘤细胞通常被嗜酸性粒细胞和肥大细胞包围,这是系统性 ALCL 中通常不存在的特征。由于白细胞介素-13与过敏有关,我们寻找了 IgE,并发现它装饰了肥大细胞和包膜及淋巴结中呈递抗原的滤泡树突状细胞的表面,但未涉及未受累的包膜。包膜和区域淋巴结内的浆细胞被鉴定为 IgE 的可能来源。综上所述,这些发现表明了一个假设,即在易感患者中,具有慢性过敏反应特征的放大免疫反应是 BIA-ALCL 发病机制的基础。